ClinicalTrials.gov
ClinicalTrials.gov Menu

The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study (ACTIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00753337
Recruitment Status : Completed
First Posted : September 16, 2008
Results First Posted : December 30, 2013
Last Update Posted : April 4, 2016
Sponsor:
Information provided by (Responsible Party):
Medtronic Endovascular

Brief Summary:
The objective of this study is to evaluate the safety and efficacy of the Assurant Cobalt Iliac Stent System in the treatment of de novo and restenotic lesions in iliac arteries of subjects with Peripheral Artery Disease (PAD).

Condition or disease Intervention/treatment Phase
Peripheral Vascular Disease Device: Assurant® Cobalt Iliac Stent System Not Applicable

Detailed Description:
This study is being conducted to collect 9 month safety and efficacy data on the Assurant Cobalt Iliac Stent for all subjects enrolled into the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study Using the Medtronic Assurant Cobalt Iliac Balloon-Expandable Stent System
Study Start Date : October 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Cobalt
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Assurant Cobalt Iliac Stent
Assurant® Cobalt Iliac Stent System
Device: Assurant® Cobalt Iliac Stent System
Iliac Stenting



Primary Outcome Measures :
  1. Major Adverse Events (MAE), Measured as Device and/or Procedure Related Death, Target Limb Loss and/or Clinically Driven Target Lesion Revascularization (TLR) or Target Vessel Revascularization (TVR). [ Time Frame: 9 months ]
    Percentage based on number of evaluable subjects for MAE. Subjects are considered unevaluable for MAE to 9 months if a) withdrawn before 240 days without having MAE events or b) lost to follow-up before 240 days without having MAE events and had no contact thereafter or c) any device and/or procedure-unrelated death before 240 days without having MAE events.


Secondary Outcome Measures :
  1. Primary Patency Rate at 9 Months [ Time Frame: 9 months ]
    Primary patency was defined as the blood flow through the treated vessel segment into the distal vasculature (e.g. the common femoral artery and/or the deep femoral artery) as evidenced by duplex ultrasound scan at 9 months for all subjects enrolled with evaluable duplex scans.

  2. Device Success [ Time Frame: 9 months ]
    Device Success defined as angiographic evidence of <30% final residual stenosis of the target lesion using only the assigned device.

  3. Lesion Success [ Time Frame: 9 months ]
    Lesion Success defined as angiographic evidence of <30% final residual stenosis of the target lesion using any percutaneous method such as baloon angioplasy or other stent.

  4. Procedure Success [ Time Frame: 9 months ]
    Procedure Success defined as angiographic evidence of <30% final residual stenosis of the target lesion after stent placement and no occurrence of a procedure related MAE prior to hospital discharge (for subjects with more than one lesion stented the worse case is counted)

  5. Clinical Success [ Time Frame: 30 days ]
    Clinical success defined as the improvement of Fontaine classification by at least one stage above the pretreated (pre-procedure) clinical value. The reported values are a percentage of limbs showing improvement.

  6. Clinical Success [ Time Frame: 9 months ]
    Clinical success defined as the improvement of Fontaine classification by at least one stage above the pretreated (pre-procedure) clinical value. The reported values are a percentage of limbs showing improvement.

  7. Hemodynamic Success [ Time Frame: 30 days ]
    Hemodynamic success defined as an improvement in ankle-brachial Index (ABI) or toe brachial index (TBI) > 0.10 over pre-procedure level and not deteriorated by > 0.15 from first post-procedure level.

  8. Hemodynamic Success [ Time Frame: 9 months ]
    Hemodynamic success defined as an improvement in ankle-brachial Index (ABI) or toe brachial index (TBI) > 0.10 over pre-procedure level and not deteriorated by > 0.15 from first post-procedure level.

  9. All Cause Mortality [ Time Frame: 30 days ]
    Subjects are considered unevaluable for all cause mortality at 30 days if a) withdrawn before 25 days or b) lost to follow-up before 25 days and had no contact thereafter.

  10. All Cause Mortality [ Time Frame: 9 months ]
    Subjects are considered unevaluable for all cause mortality at 9 months if a) withdrawn before 240 days or b) lost to follow-up before 240 days and had no contact thereafter.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The lesion(s) is either de novo or restenotic in nature, located in the common iliac artery and/or the external iliac artery;
  • The subject is symptomatic (Fontaine stage II or III) with a target lesion stenosis ≥ 50% .
  • The target vessel(s) reference diameter is ≥ 6 mm and ≤ 10 mm by visual estimate;
  • The lesion length is < 100 mm (10 cm)

Exclusion Criteria:

  • Excessive peripheral vascular disease(PVD), unresolved fresh thrombus or tortuousity,or heavily calcified.
  • Tissue loss in the target extremities.
  • The target lesion is in a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis;
  • The target lesion is in an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion.
  • The lesion requires treatment other than percutaneous transluminal angioplasty (PTA) prior to stent placement;
  • Other lesions requiring treatment or surgery within 30 days of the procedure (pre or post) with the exception of the non-target lesion(s).
  • Inadequate distal run-off.
  • History of bleeding diatheses or coagulopathy or will refuse blood transfusions;
  • Creatinine > 2.5 mg/dl
  • Platelet count <80,000 cells/mm3 or >700,000 cells/mm3, or a white blood cell (WBC) of <3,000 cells/mm3
  • Participation in another investigational device or drug study and has not completed the primary endpoint(s) or that clinically interferes with the study endpoints;
  • Previously enrolled in the Study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00753337


Locations
United States, Michigan
Michigan Vascular Research Center
Flint, Michigan, United States, 48507
United States, New York
NY Presbyterian Hospital
New York, New York, United States, 10032
Sponsors and Collaborators
Medtronic Endovascular
Investigators
Principal Investigator: Robert G Molnar, MD Michigan Vascular Research Center
Principal Investigator: William Gray, MD NY Presbyterian Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medtronic Endovascular
ClinicalTrials.gov Identifier: NCT00753337     History of Changes
Other Study ID Numbers: IP085
First Posted: September 16, 2008    Key Record Dates
Results First Posted: December 30, 2013
Last Update Posted: April 4, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Cobalt
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs